

Integrated Diagnostics Holdings PLC Strengthens Egyptian Radiology Portfolio with Radiotherapy Expansion

20 June 2025

(London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading provider of diagnostic services with operations in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan announced today that its Egyptian radiology subsidiary, Al Borg Scan, has successfully completed a strategic acquisition of CAIRO RAY for Radiotherapy, a radiology and radiotherapy facility in East Cairo, Egypt for a total consideration of EGP 400 million. The acquisition represents a landmark step forward in realizing the Company's long-term vision of building an established radiology offering alongside its already market-leading pathology business.

The 2,000 sqm medical facility, which is located within a medical hub in the capital city's affluent New El-Dokki neighbourhood, offers patients a broad range of radiology and radiotherapy services, allowing IDH to grow its radiology portfolio while adding a new, high-potential service to its offering. As part of the deal, the Group will be acquiring an operating radiotherapy business and the medical facility's real estate assets, radiotherapy equipment, human resources and commercial agreements. With this latest addition, Al Borg Scan's branch network stands at eight locations, strategically located to serve Greater Cairo's most affluent and underpenetrated neighbourhoods.

By venturing into radiotherapy, IDH is looking to capitalize on the accelerated growth witnessed in the sector in recent years while continuing to serve patients in its chosen markets with increased access to life-saving diagnostic services and treatments. Despite the sector's appealing growth profile supported by Egypt's aging population coupled with increasing cancer prevalence, supply in the segment continues to trail demand, offering new entrants and investors attractive future expansion opportunities.

Dr. Hend El Sherbini, IDH CEO, commented: "This ambitious investment package once more underscores our commitment to building a world-class radiology business in our home market. Since Al Borg Scan's launch, we have witnessed accelerated growth supported by strong underlying market fundamentals coupled with a successful market entry strategy executed by our team on the ground. By further expanding our footprint and offering, we are looking to continue on this favourable momentum to capture additional market share in the fragmented and underserved radiology and radiotherapy segments while continuing to serve our communities by ensuring we bring more specialized services and advanced technology closer to their homes. We are confident that the newly acquired facility will begin providing

contributing to the Group's results in 2026, with its full potential being realized in the coming year."

Since Al Borg Scan's initial launch in 2018, IDH has invested over EGP 600 million in the venture, with the company consistently delivering robust results. Most recently, IDH's radiology venture continued to record remarkable results, with revenues expanding 45% year-on-year to record EGP 224 million in FY 2024. Top-line growth was supported by a year-on-year rise in radiology scans performed, further highlighting the venture's growing popularity. This achievement positions Al Borg Scan to become a top-tier provider in the burgeoning Egyptian radiology and radiotherapy market.

-Ends-

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar in Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditation. The Group's portfolio of over 3,000 diagnostics tests. From its base of 628 branches as of 31 December 2024, IDH served over 100 million patients and performed more than 39.2 million tests in 2024. IDH will continue to add laboratories through its Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and European markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are admitted to the equity market (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (ticker: IDHC) since 2015.

Contact

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | tarek.yehia@idhcorp.com

Important Notice

The information contained in this announcement is deemed by the Company to constitute inside information as defined under the UK version of the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is considered to be in the public domain. MUFG Corporate Governance Limited, IDH's Company Secretary, is responsible for the release of this announcement for the purposes of such regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFFSRLIALIE